Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05545072 · ClinicalTrials.gov registry record · Phase 3
Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
A Phase 3 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT05545072 is a Phase 3 study that was terminated before completion, run by Emory University. The registered enrollment target is 5 participants.
The verdict
NCT05545072, a Phase 3 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS). Most people suffering from nasal polyps have elevated levels of white blood cells called eosinophils that are involved in inflammation of the air passages. Despite appropriate treatment with oral/topical corticosteroids, saline irrigations, and surgery, nasal polyps return frequently within months of surgery. Participants will be administered a placebo or dupilumab every two weeks for 52 weeks.
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG Intranasal Corticosteroid Sprays (INCS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2024-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05545072
The ClinicalTrials.gov registry entry for NCT05545072 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05545072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05545072 about?
NCT05545072 is a clinical study titled "Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)". The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS). Most people suffering from nasal polyps have elevated levels of white blood cells called eosinophils that are involved in inflammation of the air passages. Despite appropriate treatment with or...
What is the current status of trial NCT05545072?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2023-10-26. Estimated completion is 2024-07-10.
What interventions are being tested in trial NCT05545072?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), Intranasal Corticosteroid Sprays (INCS) (DRUG).
Who is sponsoring clinical trial NCT05545072?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.